Multi-omics pan-cancer analyses identify MCM4 as a promising prognostic and diagnostic biomarker

被引:0
作者
Yanxing Li
Wentao Gao
Zhen Yang
Zhenwei Hu
Jianjun Li
机构
[1] Xi’an Jiaotong University Health Science Center,Department of Cardiology
[2] Jincheng People’s Hospital Affiliated to Changzhi Medical College,undefined
来源
Scientific Reports | / 14卷
关键词
MCM4; Multi-omics; Pan-cancer; Bioinformatics; Immune infiltration; Prognosis; Biomarker;
D O I
暂无
中图分类号
学科分类号
摘要
Minichromosome Maintenance Complex Component 4 (MCM4) is a vital component of the mini-chromosome maintenance complex family, crucial for initiating the replication of eukaryotic genomes. Recently, there has been a growing interest in investigating the significance of MCM4 in different types of cancer. Despite the existing research on this topic, a comprehensive analysis of MCM4 across various cancer types has been lacking. This study aims to bridge this knowledge gap by presenting a thorough pan-cancer analysis of MCM4, shedding light on its functional implications and potential clinical applications. The study utilized multi-omics samples from various databases. Bioinformatic tools were employed to explore the expression profiles, genetic alterations, phosphorylation states, immune cell infiltration patterns, immune subtypes, functional enrichment, disease prognosis, as well as the diagnostic potential of MCM4 and its responsiveness to drugs in a range of cancers. Our research demonstrates that MCM4 is closely associated with the oncogenesis, prognosis and diagnosis of various tumors and proposes that MCM4 may function as a potential biomarker in pan-cancer, providing a deeper understanding of its potential role in cancer development and treatment.
引用
收藏
相关论文
共 193 条
[21]  
Li J(2005)MCM4 expression in esophageal cancer from southern China and its clinical significance J. Cancer Res. Clin. Oncol. 131 677-198
[22]  
Chuang C-H(2021)MCM4 is a novel biomarker associated with genomic instability, BRCAness phenotype, and therapeutic potentials in soft-tissue sarcoma Front. Cell Dev. Biol. 9 666376-569
[23]  
You Z(2022)MCM4 is a novel prognostic biomarker and promotes cancer cell growth in glioma Front. Oncol. 12 1004324-268
[24]  
Masai H(2018)Potential clinical value and putative biological function of miR-122-5p in hepatocellular carcinoma: A comprehensive study using microarray and RNA sequencing data Oncol. Lett. 16 6918-98
[25]  
Ishimi Y(2012)Effect of an MCM4 mutation that causes tumours in mouse on human MCM4/6/7 complex formation J. Biochem. 152 191-249
[26]  
You Z(2015)G364R mutation of MCM4 detected in human skin cancer cells affects DNA helicase activity of MCM4/6/7 complex J. Biochem. 157 561-172
[27]  
Pei L-P(2021)MCM4 is a novel biomarker associated with genomic instability, BRCAness phenotype, and therapeutic potentials in soft-tissue sarcoma Front. Cell Dev. Biol. 9 666376-104
[28]  
Zhang Y-Z(2017)An MCM4 mutation detected in cancer cells affects MCM4/6/7 complex formation J. Biochem. 161 259-1156
[29]  
Li G-Y(2007)A viable allele of Mcm4 causes chromosome instability and mammary adenocarcinomas in mice Nat. Genet. 39 93-98
[30]  
Sun J-L(2021)Immune checkpoint inhibitors for the treatment of cancer: Clinical impact and mechanisms of response and resistance Annu. Rev. Pathol. Mech. Dis. 16 223-832